Brief: Curis Announces Eleven Active Clinical Sites In TakeAim CLL Study
26/06/2026 14:56
BRIEF-Curis Announces Eleven Active Clinical Sites In TakeAim CLL Study June 26 (Reuters) - Curis Inc CRIS.O:
CURIS ANNOUNCES ELEVEN ACTIVE CLINICAL SITES IN TAKEAIM CLL STUDY, REAFFIRMS PATIENT DOSING GUIDANCE, AND REPORTS STOCKHOLDER APPROVAL OF REVERSE STOCK SPLIT
CURIS - REVERSE STOCK SPLIT APPROVED AT RATIO OF 1-FOR-5 TO 1-FOR-25
Source text: ID:nPn6jBdd1a
Further company coverage: CRIS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Curis
See all newsCuris Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Curis Announces Pricing Of $5.6 Million Public Offering
Curis Inc expected to post a loss of $7.84 a share - Earnings Preview
Curis Inc expected to post a loss of $7.47 a share - Earnings Preview
Brief: Curis Doses First Five Patients In Takeaim Cll Study